Technology ID

Real-Time PCR Assay for HIV-1 Subtype Diagnosis and Global Surveillance of Drug Resistance

Lead Inventor
Yang, Chunfu (CDC)
Devos, Joshua (CDC)
Wagar, Nicholas (CDC)
Zhou, Zhiyong (CDC)
Therapeutic Areas
Infectious Disease
Lead IC
CDC researchers have developed a patented set of RT-PCR and sequencing primers based on HIV-1 group M sequences. Evaluation of the primers using samples collected around the world demonstrated broad detection capacity for multiple HIV-1 group subtypes and predominant circulating recombinant forms. Commercially available HIV-1 drug resistance (HIVDR) genotyping assays are expensive and have limited ability to detect non-B subtypes. This optimized assay is broadly sensitive in genotyping HIV-1 group M viral strains and more sensitive than other assays in detecting mixed viral populations. This technology can be used in resource-limited settings where HIVDR surveillance is recommended to minimize the development and transmission of HIVDR.

  • Utility for HIV-1 sub-typing detection, evaluation of anti-HIV therapeutic efficacy, and HIV drug resistance (HIVDR) surveillance and monitoring
  • Rapid, accurate, and cost-effective technology easily adapted as a kit
Commercial Applications
  • HIV-1 sub-typing diagnostic
  • Evaluation of efficacy of anti-HIV therapeutics
  • HIV drug resistance (HIVDR) surveillance and monitoring
Competitive Advantages
  • Cost-effective
  • Simple to implement
  • Rapid, accurate and objectively conclusive
  • Easily implemented as a kit
  • Assay could be applicable to HIVDR genotyping in both ART-naive and ART-experienced populations
Licensing Contact:
Mitzelfelt, Jeremiah